|
gptkbp:instanceOf
|
gptkb:drug
gptkb:anticoagulant
|
|
gptkbp:approvalYear
|
2011
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
|
|
gptkbp:ATCCode
|
B01AC24
|
|
gptkbp:bioavailability
|
36%
|
|
gptkbp:brand
|
gptkb:Brilique
gptkb:Brilinta
|
|
gptkbp:CASNumber
|
274693-27-5
|
|
gptkbp:category
|
antithrombotic agent
purinergic receptor antagonist
|
|
gptkbp:chemicalFormula
|
C23H28F2N6O4S
|
|
gptkbp:contraindication
|
active bleeding
history of intracranial hemorrhage
|
|
gptkbp:developedBy
|
gptkb:AstraZeneca
|
|
gptkbp:discoveredIn
|
2003
|
|
gptkbp:drugClass
|
cyclopentyltriazolopyrimidine
|
|
gptkbp:eliminationHalfLife
|
7 hours
|
|
gptkbp:excretion
|
urine
feces
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Ticagrelor
|
|
gptkbp:interactsWith
|
strong CYP3A inhibitors
strong CYP3A inducers
other antiplatelet drugs
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
P2Y12 receptor antagonist
|
|
gptkbp:metabolism
|
gptkb:CYP3A4
|
|
gptkbp:molecularWeight
|
522.57 g/mol
|
|
gptkbp:notAProdrug
|
true
|
|
gptkbp:patentExpired
|
2024 (US)
|
|
gptkbp:pregnancyCategory
|
C (US)
B3 (Australia)
|
|
gptkbp:proteinBinding
|
99%
|
|
gptkbp:reversibleBinding
|
true
|
|
gptkbp:riskFactor
|
hyperuricemia
increased creatinine
ventricular pauses
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
bleeding
bradycardia
dyspnea
|
|
gptkbp:synonym
|
gptkb:AZD6140
|
|
gptkbp:usedFor
|
gptkb:acute_coronary_syndrome
myocardial infarction
prevention of thrombotic events
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
yes
|
|
gptkbp:bfsParent
|
gptkb:Servier_Pharmaceuticals
gptkb:Antiplatelet_agent
|
|
gptkbp:bfsLayer
|
7
|